Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL
Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NASDAQ:TGTX), has secured US FDA accelerated approval for the treatment of:
- adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen, and
- adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Accelerated approval was granted for these indications, under a priority review (MZL), based on the results of the Phase 2 UNITY-NHL Trial (NCT02793583); in MZL, an ORR of 49% with 16% complete responses and in FL an ORR of 43% with 3% complete responses were achieved, respectively. Umbralisib was earlier granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon and was discovered by Rhizen Pharma and subsequently licensed to TG Therapeutics (NASDAQ:TGTX) at an IND stage (TGR 1202) in 2012. In 2014, both parties entered into a licensing agreement as a part of which TGTX obtained worldwide rights and Rhizen has retained commercialization rights for India while also being the manufacturing and supply partner for Umbralisib.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said: “Umbralisib’s approval offers MZL & FL patients a new treatment option and is a huge validation of Rhizen’s drug discovery & development capabilities. This is a momentous occasion in Rhizen’s journey as a successful biotech that speaks of the true ability of our team to discover & develop safe and effective therapies that can last the rigors of drug development. Further, we are keen to bring Umbralisib to Indian patients and we plan to initiate activities towards registration and approval there soon.”
Pranav Amin, Chairman, Rhizen Pharmaceuticals & Managing Director of Alembic Pharmaceuticals Ltd said: “We are extremely proud of this historic milestone for Rhizen, and of the fact that Umbralisib is the first NCE discovered by Indian scientists to secure a US FDA approval. We are committed to working together with TG Therapeutics and Rhizen Pharma to ensure uninterrupted supply of UKONIQ™. Umbralisib is the first discovery asset to come out of Rhizen’s R&D efforts and this approval heralds the promise of the rest of Rhizen’s deep pipeline and continuing efforts.”
About Umbralisib:
Umbralisib is the first and only oral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. PI3K-delta is known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking and immunity and is expressed in both normal and malignant B-cells. CK1-epsilon is a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies. Umbralisib is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. More information on Umbralisib or UKONIQ™ can be found at https://www.tgtherapeutics.com/prescribing-information/uspi-ukon.pdf.
About Alembic Pharmaceuticals Ltd:
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s products that are marketed through a marketing team of over 5000 are well recognized by doctors and patients.
Information about Alembic can be found at http://www.alembicpharmaceuticals.com/.
(Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLL TD) (BSE: 533573)
About Rhizen Pharmaceuticals A.G.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in Basel, Switzerland. For additional information, please visit www.rhizen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005742/en/
Contact information
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG
+41 32 580 0113
corpcomm@rhizen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Launches PayCredit to Power Credit Innovation for Digital Banks and Fintechs22.10.2025 11:00:00 EEST | Press release
Paymentology, the leading global issuer-processor, has launched PayCredit, an advanced credit ledger platform designed to help financial institutions deliver tailored, feature rich credit products at speed, overcoming the limitations of legacy and core banking systems. Amid rising demand for flexible financial payment tools, credit cards remain a critical instrument for enabling consumer spending, managing cash flow, and deepening customer loyalty. Yet many legacy credit systems lack the flexibility to meet the expectations of today's consumers, who demand a combination of both revolving and instalment credit to help them better manage their money, whilst many modern ledgers are retrofitted from a debit architecture and struggle to provide credit processing. PayCredit was developed from the ground up with credit billing cycles and logic at its core, making it easier for issuers to build products that reflect real-world behaviours, from revolving balances to instalments and Buy Now, Pay
Infrastructure Capital Advisors Expands its Offerings into European Markets With Launch of Preferred Income UCITS ETF (PFFI) & Declares The Fund’s First Dividend22.10.2025 11:00:00 EEST | Press release
Infrastructure Capital Advisors (“Infrastructure Capital”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is celebrating the expansion of its offerings into Europe with the launch of the Infrastructure Capital Preferred Income UCITS ETF (PFFI). This actively managed ETF, which was listed in September, seeks to produce diversified income by targeting high yield income investments by predominately focusing on preferred stocks. Today,PFFI is also declaring its first dividend of $0.1335 per share ($1.602 per share on an annualized basis). The dividend will be paid on November 3, 2025 to shareholders of record as of the close of business on October 29, 2025. “We are thrilled to offer investors across a range of global markets the opportunity to benefit from our team’s active management process applied to preferred and income securities as we identify and capitalize on market inefficiencies,” said Jay Hatfield, CEO of Infrastruc
Locus Robotics Reports Record Growth Achieving 6 Billion Picks in Fastest Time Yet22.10.2025 11:00:00 EEST | Press release
Locus Robotics, the global leader in AI-driven, mobile warehouse automation, today announced its strongest growth over the past two quarters, reflecting accelerating industry adoption of Physical AI, seamlessly fusing intelligent robotics and real-world execution. Driven by surging implementations and faster time-to-value for customers, Locus Robotics recently surpassed 6 billion picks worldwide, with the last billion in just 24 weeks—the fastest pace in its history. “Our growth is driven by our customers’ success,” said Rick Faulk, CEO of Locus Robotics. “Retailers, 3PLs, and healthcare providers are seeing measurable impact faster than ever—scaling productivity in weeks, not months. Staples Canada, for example, hit one million picks just 70 days after going live, proving the immediate ROI our platform delivers.” So far this year, Locus Robotics has seen 30–40% year-over-year volume growth, with throughput reaching 200–300 units picked per second — roughly 45 million picks per week. L
Smartstream and ActiveViam Collaborate to Meet Demands for Collateral Optimisation22.10.2025 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the partnership with ActiveViam, a global provider of advanced data analytics and decision-making solutions for financial services – together the two companies will provide immediate ROI for collateral management optimisation, for clients in treasury and capital markets. This collaboration connects two technologies, Smartstream’s Smart Collateral with ActiveViam’s Atoti Collateral Optimisation solution. The result is an efficient, streamlined and cost-effective solution for optimising and allocating cheaper-to-deliver assets, whilst reducing reliance on expensive liquidity buffers. The partnership provides a comprehensive, and modular collateral management workflow for financial institutions. This powerful combination future-proofs clients and enables them to make more efficient use of their cash and non-cash collateral inventory in a timely manner. Roland Brandli
Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 10:30:00 EEST | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingham NHS Foundation Trust, today announced new overall survival (OS) insights from the PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) Study aligning with previous findings that suggest mogamulizumab may offer meaningful OS benefit for patients living with mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL).2 Key findings2: For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those not receiving mogamulizumab (n=175) at 54 months (p<0.01). Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom